Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center

Journal of Surgical Oncology

Volumn 109, Issue 7, 2014, Pages 730-739

  Huang, Chao Qun ^a   Feng, Jue Ping ^b   Yang, Xiao Jun ^a   Li, Yan ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

colorectal cancer; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; peritoneal carcinomatosis

Indexed keywords

CISPLATIN; MITOMYCIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CHINA; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COLOSTOMY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; FEMALE; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SAFETY; SEPTICEMIA;

COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; PERITONEAL CARCINOMATOSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS;

EID: 84899543191     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23545     Document Type: Article

References (37)

1. Al-Shammaa HA, Li Y, Yonemura Y,: Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 2008; 14: 1159-1166.
2. Glehen O, Osinsky D, Beaujard AC, et al.: Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 2003; 12: 729-739; xiii.
3. Sadeghi B, Arvieux C, Glehen O, et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-363.
4. Jayne DG, Fook S, Loi C, et al.: Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550.
5. Sugarbaker PH,: Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol 2010; 101: 713-724.
6. Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hypertherm icintraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2003; 21: 3737-3743.
7. Tang L, Mei LJ, Yang XJ, et al.: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: Evidence from an experimental study. J Transl Med 2011; 9: 53.
8. Yang XJ, Li Y, Hassan AHA, et al.: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: Results of 21 cases. Ann Surg Oncol 2009; 16: 345-351.
9. Yang XJ, Huang CQ, Suo T, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18: 1575-1581.
10. Sugarbaker PH,: Cytoreduction surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001; 27: 239-243.
11. Fujimoto S, Takahashi M, Koyabayashi K, et al.: Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastasis. Cancer 1992; 70: 2754-2760.
12. Sugarbaker PH,: Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43: S15-S25.
13. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22: 3284-3292.
14. National Cancer Institute: Common Terminology Criteria for Adverse Events version 4.0. Available at: http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm
15. Glehen O, Mithieux F, Osinsky D, et al.: Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol 2003; 21: 799-806.
16. Elias D, Blot F, El Otmany A, et al.: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92: 71-76.
17. Witkamp AJ, de Bree E, Kaag MM, et al.: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001; 37: 979-984.
18. Verwaal VJ, van Ruth S, Witkamp A, et al.: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71.
19. da Silva RG, Sugarbaker PH,: Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006; 203: 878-886.
20. Elias D, Raynard B, Farkhondeh F, et al.: Peritoneal carcinomatosis of colorectal origin. Gastroenterol Clin Biol 2006; 30: 1200-1204.
21. Cao C, Yan TD, Black D, et al.: A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009; 16: 2152-2165.
22. Esquivel J, Sticca R, Sugarbaker PH, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. Ann Surg Oncol 2007; 14: 128-133.
23. Elias D, Gilly F, Boutitie F, et al.: Carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-68.
24. Klaver YL, Hendriks T, Lomme RM, et al.: Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model. Br J Surg 2010; 97: 1874-1880.
25. Elias D, Lefevre JH, Chevalier J, et al.: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685.
26. Cashin PH, Graf W, Nygren P, et al.: Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: A case-control study. Ann Oncol 2012; 23: 647-652.
27. Cavaliere F, De Simone M, Virzì S, et al.: Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol 2011; 37: 148-154.
28. Pestieau SR, Sugarbaker PH,: Treatment of primary colon cancer with peritoneal carcinomatosis: Comparison of concomitant vs. delayed management. Dis Colon Rectum 2000; 43: 1341-1346.
29. Sugarbaker TA, Chang D, Koslowe P, et al.: Patterns of spread of recurrent intra-abdominal sarcoma. Cancer Treat Res 1996; 82: 65-77.
30. Glehen O, Cotte E, Schreiber V, et al.: Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91: 747-754.
31. Chen C, Peng J, Sun SR, et al.: Tapping the potential of quantum dots for personalized oncology: Current status and future perspectives. Nanomedicine (Lond) 2012; 7: 411-428.
32. Nozawa T, Enomoto T, Koshida Y, et al.: Specific enhanced expression of platelel-derived endothelial cell growth factor in submucosa of human colorectal cancer. Dis Colon Rectum 2004; 47: 2093-2100.
33. Bokemeyer C, Van Cutsem E, Rougier P, et al.: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-1475.
34. Chua TC, Morris DL, Saxena A, et al.: Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: A multicenter study. Ann Surg Oncol 2011; 18: 1560-1567.
35. Saxena A, Yan TD, Chua TC, et al.: Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2010; 17: 1291-1301.
36. Elias D,: French multi-institutional registry for colorectal peritoneal carcinomatosis. 5th peritonectomy workshop. Lyon, France, Oct 2008; Abstract.
37. Chua TC, Yan TD, Saxena A, et al.: Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009; 249: 900-907.